Pfizer (PFE) shares have been underperforming since late 2021, falling more than half from their peak and pushing the forward dividend yield to an attractive 6%.
Many investors assume a yield that high signals trouble, but the reality of Pfizer’s situation may be more nuanced and more promising than the market is pricing in.
The elevated yield reflects broad market skepticism about the company’s future, rooted largely in concerns about upcoming patent expirations across several key products.
Ibrance, Pfizer’s cancer-fighting drug, along with blood thinner Eliquis and pneumonia vaccine Prevnar 13, all face patent cliffs that threaten to dent the company’s bottom line in the near term.
Roughly one-third of Pfizer’s total revenue is exposed to these patent expirations over the next couple of years, which is a meaningful chunk of the business.
What critics tend to overlook, however, is how aggressively Pfizer has been positioning itself to replace that revenue through new pipelines and drug approvals.
The company scored a meaningful regulatory win in June with the FDA approval of Hympavzi, a treatment for hemophilia, signaling that its pipeline is actively delivering results.
CEO Albert Bourla has stated his expectation “that starting in 2029, we will enter five years of high-single-digit revenue CAGR led by the company’s cancer push,” a projection that suggests significant growth ahead.
Even if that forecast turns out to be conservative, it points to a business capable of sustaining its dividend payments through the transitional years and well beyond.
The oncology segment in particular appears to be the engine Pfizer is betting on, with multiple assets in development aimed at capturing a larger share of the cancer treatment market.
The honest challenge for investors is navigating the two to three years of likely turbulence before the new pipeline fully offsets losses from expiring patents.
Share prices could remain pressured during that window, even as the underlying dividend remains reasonably well protected by existing cash flows and management’s strategic planning.
For income-focused investors with a patient outlook, that transitional period may represent an entry point rather than a warning sign, particularly at a 6% forward yield.
The crowd appears to be treating Pfizer’s situation as a trap, but the evidence suggests the pharmaceutical giant has done significant work to prepare for its patent challenges and emerge stronger on the other side.
